[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100434503":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":41,"responsibleParty":57,"collaborators":25,"id":59,"slug":25,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Istituto Ortopedico Rizzoli","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Autologous PRP injection","EXPERIMENTAL","This group of patients will be treated with single intra-articular injection of Autologous PRP.",[13],"Procedure: Autologous PRP injection",{"label":15,"type":16,"description":17,"interventionNames":18},"HA injection","ACTIVE_COMPARATOR","This group of patients will be treated with single intra-articular injection of Hyaluronic Acid (HA)",[19],"Procedure: HA injection",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Patients will be treated with a single injection of Autologous PRP (5 ml) in the knee joint affected by patellofemoral osteoarthritis",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Patients will be treated with a single injections of Hyaluronic Acid (5 ml) in the knee joint affected by patellofemoral osteoarthritis",[15],[30],{"name":31,"affiliation":5,"role":32},"Alessandro Di Martino, MD","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Roberta Licciardi, MSc","CONTACT","0516366567","roberta.licciardi@ior.it",{"name":31,"role":36,"phone":25,"phoneExt":25,"email":40},"alessandro.dimartino@ior.it",[42],{"facility":5,"status":43,"city":44,"state":25,"zip":25,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Bologna","Italy",{"type":47,"coordinates":48},"Point",[49,50],11.33875,44.49381,{"lat":50,"lon":49},[53,56],{"name":31,"role":36,"phone":54,"phoneExt":55,"email":40},"6366567","051",{"name":35,"role":36,"phone":54,"phoneExt":55,"email":38},{"type":58,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100434503",false,"NCT04937998","PRP Versus HA IN OSTEOARTHRITIS OF THE PATELLOFEMORAL JOINT","THE USE OF FRESH PRP VS HA IN THE TREATMENT OF OSTEOARTHRITIS OF THE PATELLOFEMORAL JOINT Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age between 30 and 65;\n2. Signs and symptoms of isolated patellofemoral osteoarthritis present in one or both knees;\n3. Radiographic signs of isolated patellofemoral osteoarthritis (according to Iwano et al stage 1-3 classification) or chondropathy (assessed on MRI) with K-L grade of the other compartments ≤ 2. \\[PMID: 2302884 - PMID: 27979409\\] ;\n4. Hemoglobin \\> 11 g\u002Fdl; Platelet count \\> 150,000 plt\u002Fmm3 (Recently performed CBC exam);\n5. No clinically significant electrocardiographic alterations (Recently performed ECG).\n6. Ability and consent of patients to actively participate in clinical follow-up;\n7. Signature of informed consent.\n\nExclusion Criteria:\n\n1. Patients unable to express consent;\n2. Patients who have undergone intra-articular infiltration of another substance within the previous 6 months;\n3. Patients undergoing knee surgery within the previous 12 months;\n4. Patients with malignant neoplasms;\n5. Patients with rheumatic diseases;\n6. Patients with diabetes;\n7. Patients with hematologic diseases (coagulopathies);\n8. Patients on anticoagulant-antiaggregant therapy;\n9. Patients with thyroid metabolic disorders;\n10. Patients abusing alcoholic beverages, drugs or medications;\n11. Body Mass Index \\> 35;\n12. Patients who have taken NSAIDs in the 3 days prior to blood draw;\n13. Patients with cardiovascular disease for which a 60 mL blood draw would be contraindicated;\n14. Patients with a recently performed blood test with Hb\\\u003C 11 g\u002Fdl and Platelets \\\u003C 150,000 plt\u002Fmm3.\n15. Previous treatment of patellar dislocation\n16. Iwano score of grade 4.","ALL","30 Years","65 Years",{"count":69,"type":70},166,"ESTIMATED","INTERVENTIONAL",[73],"NA","The aim of the study is to compare the 12-month clinical outcomes of patients with patellofemoral osteoarthritis undergoing infiltrative treatment with fresh PRP and HA",[76],"Patellofemoral Osteoarthritis",[78,79,80,81,82,15,83,84,85,86],"PRP","HA","Osteoarthritis","Autologous PRP","PRP injection","injection treatment","Randomized controlled trial","Hyaluronic Acid","Platelet rich plasma","2025-12-03",{"date":89,"type":90},"2025-12-04","ACTUAL",{"date":92,"type":90},"2022-10-26",{"date":94,"type":70},"2026-09",{"name":5,"class":6},1]